What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The drug product (DP) is designated as APR-2020 and is composed of autologous human CD34+ cells derived from each clinical patient with RPS19-deficient DBA that have been transduced ex vivo with the drug substance.”In the company’s words, NCT07476183 on ClinicalTrials.gov
- Tested for
- RPS19 Deficient Diamond-Blackfan Anemia
- Main trialPhase 1
- “Brief summary The goal of this clinical trial is to learn if APR-2020 is safe and can help treat Diamond-Blackfan Anemia (DBA) in adolescents and children. The main questions it aims to answer are: * Is APR-2020 safe and well tolerated? * Does APR-2020 modify or correct an underlying genetic condition which causes DBA? * Does APR-2020 reduce or eliminate the need for blood transfusions and/or restore certain blood counts affected by DBA? Participants will: * Take the drug one time as an infusion. * Undergo two rounds of a cellular harvest procedure in which their own cells will be used in…”In the company’s words, NCT07476183 on ClinicalTrials.gov
- Other names
- Cell Therapy
Coming up1
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Apr 2027 | Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026